FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (NYSE American: FOXO) is an insurtech company focused on applying epigenetic biomarker science to life insurance underwriting and product development, aiming to enable more precise longevity risk assessment. The company went public through a de-SPAC merger with CF Acquisition Corp. VIII, a blank-check vehicle sponsored by Cantor Fitzgerald that completed its IPO in 2020; the business combination closed in September 2022. This May 2021 Form 10-Q was filed ahead of the merger announcement, reflecting the company's status as a pre-merger reporting entity within the insurance technology sector. Post-combination, FOXO operates as a publicly traded insurtech issuer. For full filing history, deal timelines, and sponsor data on FOXO Technologies and thousands of other SPAC transactions, sign up for complete access at SpacDesk.